Item 7.01 Regulation FD Disclosure.

On January 20, 2021, Ocular Therapeutix, Inc. (the "Company") announced its intent to present interim data at the Glaucoma 360 Conference from the Company's ongoing multi-center, open-label, dose-escalation, proof-of-concept Phase 1 clinical trial of product candidate OTX-TIC compared to topical travoprost eye drops in patients with primary open-angle glaucoma or ocular hypertension. OTX-TIC is a bioresorbable hydrogel implant incorporating travoprost that is designed to be administered by a physician as an intracameral injection with an initial target duration of drug release of four to six months. Information to be provided during such presentation is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.






 (d) Exhibits:




                  Ocular Therapeutix, Inc. slide presentation, dated January
         99.1   2021

                Cover Page Interactive Data File (embedded within the Inline XBRL
       104      document)

© Edgar Online, source Glimpses